Teladoc Health Shares Extend Winning Streak to Seven Days
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Stock Price Surge: Teladoc Health shares rose over 6% on Thursday, extending their winning streak to seven consecutive sessions, with the stock climbing from $6.93 on June 10 to approximately $8.07, reflecting strong market rebound and restored investor confidence.
- Outstanding Monthly Performance: Over the past month, Teladoc's shares have surged 27%, with year-to-date gains reaching 10%, outperforming the S&P 500's 8.3% increase, indicating the company's relative strength in the market.
- Business Model Transformation: The company is transitioning from a cyclical direct-to-consumer telehealth model to a higher-margin, data-driven business-to-business healthcare platform, which analysts believe will lay the groundwork for future growth and profitability.
- Improved Financial Health: Analysts highlighted improving EBITDA margins, positive free cash flow, and a stronger balance sheet as indicators that Teladoc is entering a more scalable profitability phase, potentially supporting a future valuation re-rating.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TDOC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TDOC
Wall Street analysts forecast TDOC stock price to rise
15 Analyst Rating
3 Buy
12 Hold
0 Sell
Hold
Current: 7.590
Low
7.50
Averages
8.91
High
12.00
Current: 7.590
Low
7.50
Averages
8.91
High
12.00
About TDOC
Teladoc Health, Inc. provides virtual healthcare services. Its segments include Teladoc Health Integrated Care (Integrated Care) and BetterHelp. Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed on a B2B basis. BetterHelp segment includes direct-to-consumer mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs. Its Telecare brand is a tech-enabled provider of specialist and allied health care via virtual delivery.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Stock Price Surge: Teladoc Health shares rose over 6% on Thursday, extending their winning streak to seven consecutive sessions, with the stock climbing from $6.93 on June 10 to approximately $8.07, reflecting strong market rebound and restored investor confidence.
- Outstanding Monthly Performance: Over the past month, Teladoc's shares have surged 27%, with year-to-date gains reaching 10%, outperforming the S&P 500's 8.3% increase, indicating the company's relative strength in the market.
- Business Model Transformation: The company is transitioning from a cyclical direct-to-consumer telehealth model to a higher-margin, data-driven business-to-business healthcare platform, which analysts believe will lay the groundwork for future growth and profitability.
- Improved Financial Health: Analysts highlighted improving EBITDA margins, positive free cash flow, and a stronger balance sheet as indicators that Teladoc is entering a more scalable profitability phase, potentially supporting a future valuation re-rating.
See More
- Insider Share Sale: Fernando M. Rodrigues, President of BetterHelp, sold 9,572 shares of Teladoc stock valued at approximately $71,000, indicating a complete divestment of his direct holdings and potentially signaling reduced confidence in the company's future prospects.
- Significant Transaction Size: This sale represents the largest of Rodrigues's two reported open-market transactions, with the previous sale being only 3,558 shares, suggesting a fundamental shift in his stance towards Teladoc that may impact investor sentiment.
- Weak Stock Performance: Teladoc shares opened at $7.40 and closed at $7.09 on the transaction date, with a 3.03% decline over the past year, starkly contrasting with the S&P 500's nearly 80% return, highlighting the challenges the company faces in the market.
- Poor Financial Health: Despite reporting $614 million in revenue in its latest earnings report, Teladoc incurred a net loss of $171 million over the past 12 months, indicating ongoing struggles with profitability, prompting investors to closely monitor the effectiveness of its strategic transition.
See More
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Teladoc Health, Inc. breached their fiduciary duties, which could impact corporate governance and shareholder rights.
- Contingent Fee Arrangement: The firm offers to handle the matter on a no-cost basis, meaning shareholders can pursue their rights without upfront legal fees, thereby reducing financial risk associated with participation.
- Potential Remedies: Long-term shareholders may seek corporate governance reforms, return of funds, or court-approved financial incentives, which could enhance company transparency and management effectiveness.
- Importance of Shareholder Involvement: Shareholder participation can improve company policies and oversight mechanisms, enhancing transparency and accountability, which ultimately boosts overall shareholder value and promotes long-term corporate health.
See More
- Partnership Expansion: Teladoc's collaboration with Walmart aims to provide virtual urgent care, dermatology, and nutrition services through the Better Care Services platform, targeting uninsured or underinsured demographics, which is expected to broaden its customer base.
- Service Details: The offerings include 24/7 virtual urgent care, dermatology consultations with a 24-hour turnaround, and nutrition coaching, priced at $89 per visit, with prescriptions sent to any pharmacy, including Walmart.
- Market Reaction: Following the announcement of the partnership, Teladoc's shares rose over 7%, surpassing the 200-day moving average, indicating a positive market response to the collaboration.
- Strategic Implications: Bank of America views this partnership as a 'modest positive' for Teladoc, although it does not expect significant financial impacts in the near term; nonetheless, it enhances Teladoc's service integration within retail platforms, boosting brand visibility.
See More
- Collaboration Expansion: Teladoc Health announced that its virtual care services are now available through Walmart's Better Care Services platform, aiming to enhance access to healthcare, particularly for uninsured customers.
- Service Offerings: The new partnership allows Walmart customers to access various medical services, including 24/7 care, dermatology, and nutrition services, for $89 per visit, significantly improving the healthcare experience for shoppers.
- Market Strategy: Teladoc's president, Kelly Bliss, emphasized that Walmart is a primary destination for everyday needs for millions of Americans, and integrating healthcare services into the shopping experience enhances brand penetration in the market.
- Historical Collaborations: This partnership is part of Teladoc's ongoing collaboration with Walmart, following its 2025 partnership with Amazon to offer diabetes and hypertension management programs, showcasing its strategic positioning in retail and online platforms.
See More
- Subpar Financial Performance: In its first quarter update, Teladoc reported a 2% year-over-year revenue decline to $613.8 million, and while the net loss per share improved from $0.53 to $0.36, the company remains unprofitable, indicating significant challenges in regaining growth momentum.
- Decline of BetterHelp Segment: Once a key growth driver, BetterHelp has seen both revenue and paying users drop by 9% year-over-year, highlighting difficulties in sustaining growth in a competitive market, which negatively impacts overall company performance.
- International Expansion Potential: Despite overall struggles, Teladoc's international revenue increased by 17% year-over-year to $122.3 million, suggesting potential for future revenue growth as the company taps into global markets.
- Uncertain Future of AI Tools: Teladoc's plans to introduce AI products to boost revenue face uncertainty regarding their effectiveness, and combined with ongoing losses and fierce competition, investors remain cautious about the company's ability to achieve profitability in the future.
See More











